Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Revenue of Repare Therapeutics Inc. (RPTX)
Revenue in 2023 (TTM): $51.13 M
According to Repare Therapeutics Inc.'s latest financial reports the company's current revenue (TTM) is $51.13 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Repare Therapeutics Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $51.13 M | $49.18 M | $-112,809,000 | $-101,715,000 | $-93,796,000 |
| 2022 | $131.83 M | $127.65 M | $-20,104,000 | $-13,900,000 | $-29,047,000 |
| 2021 | $7.6 M | $4.26 M | $-108,516,000 | $-108,586,000 | $-106,908,000 |
| 2020 | $135 K | $-1,652,000 | $-53,638,000 | $-54,742,000 | $-53,417,000 |
| 2019 | $ | $-968,000 | $-26,484,000 | $-27,021,000 | $-27,216,000 |
| 2018 | $ | $-407,000 | $-12,121,000 | $-14,248,000 | $-14,283,000 |
| 2017 | $ | $-102,000 | $-5,926,000 | $-7,796,000 | $-7,796,000 |